Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Patent metadata

Field	Value
Publication number	US-12485145-B2
Application number	US-202418957327-A
Country	US
Kind code	B2
Filing date	Nov 22, 2024
Priority date	Mar 29, 2017
Publication date	Dec 2, 2025
Grant date	Dec 2, 2025

Abstract

The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

First claim

What is claimed is:

1 . A method for expanding tumor infiltrating lymphocytes (TILs) into a therapeutic population of TILs, the method comprising:
(a) obtaining a first population of TILs from a tumor resected from a subject by processing a tumor sample obtained from the subject into multiple tumor fragments; (b) adding the tumor fragments into a closed system; (c) performing a first expansion by culturing the first population of TILs in a cell culture medium comprising IL-2 to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas permeable surface area, wherein the first expansion is performed for about 7-11 days to obtain the second population of TILs, and wherein the transition from step (b) to step (c) occurs without opening the system; (d) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 7-12 days to obtain the third population of TILs, wherein the second expansion is performed in a closed container providing a second gas permeable surface area, and wherein the transition from step (c) to step (d) occurs without opening the system; (e) harvesting the therapeutic population of TILs obtained from step (d), wherein the transition from step (d) to step (e) occurs without opening the system; (f) transferring the harvested TIL population from step (e) to an infusion bag, wherein the transfer from step (e) to (f) occurs without opening the system; and (g) cryopreserving the infusion bag comprising the harvested TIL population from step (f) using a cryopreservation process.

2 . The method according to claim 1 , wherein the first expansion in step (c) is performed for about 11 days.

3 . The method according to claim 1 , wherein the second expansion in step (d) is performed for about 11 days to about 12 days.

4 . The method according to claim 1 , wherein the second expansion in step (d) is performed for about 11 days.

5 . The method according to claim 1 , wherein the second expansion in step (d) is performed for about 12 days.

6 . The method according to claim 1 , wherein the second expansion in step (d) is performed for about 288 hours.

7 . The method according to claim 1 , wherein the first expansion in step (c) is performed for about 11 days and the second expansion in step (d) is performed for about 11 days to about 12 days.

8 . The method according to claim 1 , wherein the first expansion in step (c) is performed for about 11 days and the second expansion in step (d) is performed for about 12 days.

9 . The method according to claim 1 , wherein steps (a) through (f) are performed in about 14 days to about 23 days.

10 . The method according to claim 1 , wherein steps (a) through (f) are performed in about 22 days to about 23 days.

11 . The method according to claim 1 , wherein steps (a) through (f) are performed in about 23 days.

12 . The method according to claim 1 , wherein about 30 to about 60 tumor fragments are added to the closed system in step (b).

13 . The method according to claim 1 , wherein the first expansion is performed in a closed container bioreactor.

14 . The method according to claim 13 , wherein the closed container bioreactor is a G-REX-100MCS bioreactor.

15 . The method according to claim 1 , wherein the second expansion is performed in a closed container bioreactor.

16 . The method according to claim 15 , wherein the closed container bioreactor is a G-REX-500MCS bioreactor.

17 . The method according to claim 1 , wherein the therapeutic population of TILs harvested in step (e) comprises sufficient TILs for use in administering a therapeutically effective dosage to a subject.

18 . The method according to claim 17 , wherein the number of TILs sufficient for administering a therapeutically effective dosage is from about 1×10 9 to about 10×10 10 .

19 . The method according to claim 17 , wherein the number of TILs sufficient for administering a therapeutically effective dosage is from about 7×10 9 to about 10×10 10 .

20 . The method according to claim 1 , wherein the APCs are peripheral blood mononuclear cells (PBMCs).

21 . The method according to claim 20 , wherein the PBMCs are supplemented at a ratio of about 1:25 TIL:PBMCs.

Assignees

• Iovance Biotherapeutics Inc

Inventors

• Wardell Seth
• Bender James
• Lotze Michael T

Classifications

• C12N2501/2321

  Interleukin-21 (IL-21) · CPC title

• C12N2501/2315

  Interleukin-15 (IL-15) · CPC title

• C12N5/0636

  T lymphocytes · CPC title

• A61K40/50

  characterised by the use of allogeneic cells · CPC title

• A61K40/428

  Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor · CPC title